Company Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Brian Strem |
Contact Details
Address: 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 United States | |
| Phone | 858 224 9600 |
| Website | kiorapharma.com |
Stock Details
| Ticker Symbol | KPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372514 |
| CUSIP Number | 49721T101 |
| ISIN Number | US49721T3095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian M. Strem Ph.D. | President, Chief Executive Officer and Director |
| Melissa Tosca CPA | Chief Financial Officer |
| Dr. Eric J. Daniels M.B.A., M.D. | Chief Development Officer |
| Dr. Stefan Sperl Ph.D. | Executive Vice President of CMC and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 8-K | Current Report |